| 2025-12-07 |
详情>>
内部人交易：
Sherman Jeffrey Scott股份减少11938.00股
|
| 2025-10-28 |
详情>>
股本变动：
变动后总股本12938.78万股
|
| 2025-10-28 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.77美元,归母净利润-9814.4万美元,同比去年增长-54.8%
|
| 2025-10-28 |
财报披露：
美东时间 2025-10-28 盘前发布财报
|
| 2025-07-29 |
详情>>
业绩披露：
2025年中报每股收益-0.56美元,归母净利润-7101.5万美元,同比去年增长-55.38%
|
| 2025-04-29 |
详情>>
业绩披露：
2025年一季报每股收益-0.2美元,归母净利润-2592.3万美元,同比去年增长4.21%
|
| 2025-04-08 |
股东大会：
将于2025-05-22召开股东大会
会议内容 ▼▲
- 1.To elect nine directors from the nominees named in the attached Proxy Statement.
2.To approve, on a non-binding advisory basis, executive compensation.
3.To recommend, on a non-binding advisory basis, the frequency of future advisory votes on the compensation paid to our named executive officers.
4.To approve the First Amendment of the NeoGenomics, Inc. 2023 Equity Incentive Plan.
5.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2025.
6.To consider any other business properly brought before the 2025 Annual Meeting.
|
| 2025-02-18 |
详情>>
业绩披露：
2022年年报每股收益-1.16美元,归母净利润-1.44亿美元,同比去年增长-1628.17%
|
| 2025-02-18 |
详情>>
业绩披露：
2024年年报每股收益-0.62美元,归母净利润-7872.6万美元,同比去年增长10.51%
|
| 2024-11-05 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.5美元,归母净利润-6340.2万美元,同比去年增长13.91%
|
| 2024-07-30 |
详情>>
业绩披露：
2024年中报每股收益-0.36美元,归母净利润-4570.3万美元,同比去年增长17.09%
|
| 2024-07-30 |
详情>>
业绩披露：
2023年中报每股收益-0.44美元,归母净利润-5512.6万美元,同比去年增长34.92%
|
| 2024-04-30 |
详情>>
业绩披露：
2024年一季报每股收益-0.21美元,归母净利润-2706.1万美元,同比去年增长12.13%
|
| 2024-04-08 |
股东大会：
将于2024-05-23召开股东大会
会议内容 ▼▲
- 1.To elect nine directors from the nominees named in the attached Proxy Statement.
2.To approve, on a non-binding advisory basis, executive compensation.
3.To approve the Fourth Amendment of the Employee Stock Purchase Plan (as amended and restated).
4.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2024.
5.To consider any other business properly brought before the 2024 Annual Meeting.
|
| 2024-02-20 |
详情>>
业绩披露：
2023年年报每股收益-0.7美元,归母净利润-8796.8万美元,同比去年增长39.02%
|
| 2023-11-06 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.59美元,归母净利润-7364.2万美元,同比去年增长39.42%
|
| 2023-04-07 |
股东大会：
将于2023-05-25召开股东大会
会议内容 ▼▲
- 1.To elect eight directors from the nominees named in the attached Proxy Statement.
2.To approve, on a non-binding advisory basis, executive compensation.
3.To approve the NeoGenomics, Inc. 2023 Equity Incentive Plan.
4.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2023.
5.To consider any other business properly brought before the 2023 Annual Meeting.
|
| 2022-04-14 |
股东大会：
将于2022-06-02召开股东大会
会议内容 ▼▲
- 1.To elect seven directors from the nominees named in the attached Proxy Statement.
2.To approve, on a non-binding advisory basis, executive compensation.
3.To approve the Third Amendment of the Employee Stock Purchase Plan (as amended and restated).
4.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2022.
5.To consider any other business properly brought before the 2022 Annual Meeting.
|
| 2022-03-29 |
复牌提示：
2022-03-28 16:00:51 停牌，复牌日期 2022-03-28 16:40:00
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-15 |
股东大会：
将于2021-05-27召开股东大会
会议内容 ▼▲
- 1. To elect nine directors from the nominees named in the attached Proxy Statement.
2. To approve, on a non-binding advisory basis, executive compensation
3. To approve the Second Amendment of the Amended and Restated Equity Incentive Plan.
4. To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2021.
5. To consider any other business properly brought before the Annual Meeting.
|
| 2020-04-15 |
股东大会：
将于2020-05-28召开股东大会
会议内容 ▼▲
- 1.To elect nine directors from among the nominees named in the attached Proxy Statement.
2.To approve, on a non-binding advisory basis, executive compensation.
3.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2020.
4.To consider any other business properly brought before the Annual Meeting.
|
| 2019-04-22 |
股东大会：
将于2019-06-06召开股东大会
会议内容 ▼▲
- 1.To elect eight directors from among the nominees named in the attached Proxy Statement.
2.To approve, on a non-binding advisory basis, executive compensation.
3.To approve, on a non-binding advisory basis, the frequency of future advisory votes on the compensation paid to our named executive officers.
4.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2019.
5.To consider any other business properly brought before the Annual Meeting.
|
| 2018-04-30 |
股东大会：
将于2018-06-20召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors, John Schmid, Linda M. Szyper and Beth Hecht, to hold office until the 2021 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal;
2.To ratify the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.To transact any other business that properly comes before the Annual Meeting (including adjournments and postponements thereof).
|
| 2018-04-20 |
股东大会：
将于2018-06-01召开股东大会
会议内容 ▼▲
- 1. Election of Directors. To elect eight (8) members of our Board, each to hold office for a one (1) year term ending on the date of the next succeeding annual meeting of stockholders or until such director's successor shall have been duly elected and qualified.
2.Amendment of the Amended and Restated Employee Stock Purchase Plan.
3.Ratification of Appointment of Independent Registered Public Accounting Firm.
|
| 2017-04-25 |
股东大会：
将于2017-05-25召开股东大会
会议内容 ▼▲
- 1. Election of Directors. To elect nine members of our Board, each to hold office for a one year term ending on the date of the next succeeding annual meeting of stockholders or until such director’s successor shall have been duly elected and qualified.
2. Amendment of the Amended and Restated Equity Incentive Plan. To approve the amendment of our Amended and Restated Equity Incentive Plan.
3. Amendment of Employee Stock Purchase Plan. To approve the amendment of our Employee Stock Purchase Plan.
4. Ratification of Appointment of Independent Registered Public Accounting Firm.
|
| 2016-05-16 |
股东大会：
将于2015-12-21召开股东大会
会议内容 ▼▲
- 1. a proposal to approve the issuance of the NEOSharesto GE Medical in the Transaction (the “Stock Issuance”);
2. a proposal to approve an amendment to Article Fourth(A) of our Articles of Incorporation to increase our authorizedsharesof common stock by 150.0millionsharesto an aggregate of 250.0millionshares(the “Authorized Common Stock Charter Amendment”);
3. a proposal to approve an amendment to Article Fourth(A) of our Articles of Incorporation to increase our authorizedsharesof preferred stock by 40.0millionsharesto an aggregate of 50.0millionshares(the “Authorized Preferred Stock Charter Amendment”);
4. a proposal to approve and adopt the Purchase Agreement and the Transaction contemplated thereby (the “Transaction Proposal”);
5. a proposal to approve an amendment and restatement of our Amended and Restated Equity Incentive Plan to increase the authorized number ofsharesof common stock available and reserved for issuance under the plan by 3.0millionsharesto an aggregate of 12.5millionsharesand to clarify provisions regarding restrictions of the repricing of options and stock appreciation rights (collectively, the “Equity Incentive Plan Amendment”);
6. a proposal to adjourn the special meeting, if necessary or appropriate, to solicit additional votes and proxies if there are insufficient votes at the time of the special meeting to approve the foregoing proposals.
|
| 2016-04-29 |
股东大会：
将于2016-06-07召开股东大会
会议内容 ▼▲
- 1.Election Of Directors;
2.Advisory Vote On Executive Compensation.
|
| 2015-05-19 |
股东大会：
将于2015-06-12召开股东大会
会议内容 ▼▲
- 1. Election of Directors. To elect eight (8) members of our Board, each to hold office for a one (1) year term ending on the date of the next succeeding annual meeting of stockholders or until such director’s successor shall have been duly elected and qualified.
2. Amendment of the Amended and Restated Equity Incentive Plan. To approve that the Company’s Amended and Restated Equity Incentive Plan (the “Plan”) be amended to add 2,500,000 shares of the Company’s common stock to the reserve available for new awards.
|